Killed To Order

What would you do if a doctor told you your time was running out—and then a nurse whispered, “You better seek alternative treatment”? In Killed To Order, Michael E. Karohs (as told to Erika M. Karohs, Ph.D.) argues that medical cannabis—especially whole-plant cannabis oil—can not only help you manage cancer symptoms, but may directly kill cancer cells, prevent their spread, and help you stay in remission. Drawing from his near-death hospitalization, a Hodgkin’s lymphoma diagnosis, surgery, the threat of chemotherapy and radiation, and then a turn to cannabis, Karohs contends that a disciplined, legally compliant, evidence-informed cannabis regimen can be a patient’s lifeline when conventional paths feel limited or intolerable.

At the core of the book is a simple claim: your body is wired with an endocannabinoid system (ECS) that regulates balance across brain, immune, gut, and more. Phytocannabinoids from cannabis—like THC and CBD—can plug into this system, selectively killing malignant cells while sparing healthy ones, slowing tumor blood vessel growth, inhibiting metastasis, and even prompting cancer cells to self-destruct. Karohs argues you can harness this biology most powerfully through properly made cannabis oil, taken in a thoughtfully staged protocol he calls SHORAK, and supported by practical choices about delivery methods, dosing, strain selection, terpenes, diet, and legality.

From crisis to conviction

Karohs was rushed to emergency care in late 2012 after losing nearly 100 pounds and suffering unbearable pain. Surgeons removed a massive, aggressive tumor; pathology identified Hodgkin’s lymphoma. The recommended path was five chemotherapy agents and possible radiation. While grateful to his medical team for saving his life, he began a rigorous search for adjuncts and alternatives, spurred by a whispered tip from a nurse and reports that chemo may, in some cases, spur protein cascades (like WNT16B) that toughen tumors (see the Fred Hutchinson group’s work cited in the book). He also surfaced studies pointing to cannabinoids’ antitumor effects in glioblastoma, melanoma, leukemia, pancreas, breast, and more (with research from Israel, California Pacific Medical Center, and others).

A pivotal discovery for him was a German study noting cannabinoid receptor expression in Hodgkin’s lymphoma, suggesting a mechanistic rationale for cannabis in his specific cancer. He obtained a legal medical recommendation, committed to cannabis, and—after months—received confirmation of no evidence of disease. In December 2014 he was declared cured. This arc becomes the book’s frame: respect standard care, know the risks and limits, and if you choose cannabis, do it methodically, legally, and consistently.

What you’ll learn

You’ll get a primer on the endocannabinoid system (Raphael Mechoulam’s work features prominently), a plain-English tour of THC, CBD, minor cannabinoids, terpenes, and flavonoids, and how these compounds act in concert—the “entourage effect” (Ben-Shabat & Mechoulam). Karohs contrasts delivery routes—smoking, vaporizing, edibles, suppositories—and makes a case for oil as the most potent, adaptable, and economical medicine when purity and process are right. He details solvent choices (favoring food-grade alcohol and warning against petroleum naptha), step-by-step extraction methods, decarboxylation nuance, storage tips, and critical safety cautions (ventilation, fire safety).

The heart of the book is the SHORAK protocol: a staged plan that begins with a hempseed-oil-supported “starter” phase to prime ECS receptors, progresses through “pre-treatment” and “full-treatment” dosing (divided into multiple daily micro-doses to keep constant pressure on cancer), and concludes with a “post-treatment” phase for immune recovery and relapse prevention. He underscores an often-missed concept—CBD’s biphasic dose-response—and explains why “more” can be counterproductive, advocating the smallest effective dose consistently applied. Along the way, he argues for dietary omega-3s to maintain functional CB1 receptors (he favors hempseed oil), and he cautions about sugar-heavy edibles and their insulin/IGF implications (echoing integrative oncologists like Dr. Donald Abrams and Dr. Andrew Weil).

Why this matters for you

If you or a loved one are navigating cancer, the book offers a self-advocacy roadmap: know your legal options, verify your physician recommendation, vet dispensaries, avoid “CBD-only” industrial hemp scams, and understand that strain choice matters (for cannabinoids, terpenes, and effects). Karohs even breeds and ages his own medical strains—Senior, RS-2017, RS-31, CBD-OD, and a tongue-in-cheek “Elephant oil” cultivar—arguing that landrace genetics, careful hybridization, and maturity translate to richer therapeutic profiles. You also get the human stories: Stan (stage 4 lymphoma and leukemia) reaching remission; Andrea (metastatic pancreatic) reporting normalized markers; Viola (bladder cancer) off chemo; Bill (suspected colon relapse) clearing subsequent scans; and Dave (stage 4 colon) rebounding on a custom, high-THC/CBD oil after setbacks.

Whether you view this as an alternative, a complement, or an exploration, the book’s value is its concreteness: specific temps for vaporization, explicit dose timing, repeatable oil-making SOPs, and a candid discussion of what derails patients (psychological reversal, nonadherence, unrealistic dosing). Read it as a patient’s playbook—one that urges hope, discipline, and informed choice.

Karohs begins where most cancer guides don’t: inside your body’s own cannabinoid network. The endocannabinoid system (ECS) is a signaling web with receptors (CB1 and CB2) spread through your brain, immune organs, gut, vasculature, bones, glands, and reproductive tissues. It helps you maintain homeostasis—your body’s equilibrium—when stress, injury, or disease threaten balance. The surprising twist? Plant cannabinoids from cannabis look familiar to your ECS. They dock to those same receptors, often with stronger affinity than your self-made endocannabinoids.

What CB1 and CB2 really do

CB1 receptors cluster in your brain and nervous system, but also appear in fat, gut, lungs, and reproductive organs. CB2 lives heavily in immune tissues (spleen, lymph cells) and shows up in liver, heart, bones, kidneys, endocrine glands, and more. Karohs highlights a key implication: cancer is not just a rogue growth—it hijacks immune and inflammatory pathways the ECS modulates. That’s why, he argues, CB receptors on tumors (as seen in a German study of Hodgkin’s lymphoma) make cannabis mechanistically relevant.

How cannabis might fight cancer

Karohs synthesizes research streams to paint a multi-pronged model:

• Selective apoptosis: Cannabinoids can trigger programmed death in malignant cells while largely sparing healthy ones.
• Anti-proliferation: They may slow tumor cell division.
• Anti-angiogenesis: They can inhibit the formation of blood vessels that feed tumors.
• Anti-metastasis: They appear to impede migration and invasion of cancer cells.
• Autophagy activation: They can spur tumor cells to consume themselves—“self-eating” that prunes diseased components.

Add to that cannabis’ anti-inflammatory effects that may help prevent malignant transformation in the first place. This multi-mechanism picture is why Karohs calls cannabis “completely anti-cancer” in intent, in contrast to cytotoxic regimens that can injure healthy tissues. He cites chemotherapy’s potential to increase survival factors between cycles (e.g., WNT16B), which can harden tumors against subsequent treatment (a point echoed in oncology debates over adaptive resistance).

A cautionary parable: blocking CB1

If activating cannabinoid receptors can be healing, what happens when you block them? Karohs recounts the rise and fall of Rimonabant, a CB1 antagonist sold for weight loss in Europe. Reports of anxiety, depression, accidents, and worsened neurodegeneration piled up; animal data flagged colon polyp increases. Regulators withdrew it. The lesson he draws for you: the ECS seems vital in guarding mood, immunity, metabolism, and oncologic risk; bluntly interfering may backfire.

Feed your receptors: Omega-3 and ECS tone

An unusually practical thread ties diet to receptor function. Karohs argues that Omega-3 fatty acids are structural building blocks for healthy CB1 receptors; deficiency can leave receptors “uncoupled,” degrading ECS signaling (this view is shared by cannabis educators like “Granny Storm-Crow” and echoed in basic lipid biology). He recommends hempseed oil—rich in a balanced omega-6:omega-3 profile—to restore receptor integrity over weeks, which is why his protocol begins with a hempseed-supported starter phase. If you’ve tried cannabis and felt “nothing,” he suggests your ECS may need this nutritional priming first.

Contextual note: While the author spotlights many promising preclinical and early clinical findings, oncology consensus still calls for more robust, controlled human trials across cancer types to define indications, combinations, and dosing (see integrative oncology texts by Donald Abrams and Andrew Weil for balanced perspectives). The takeaway for you isn’t certainty; it’s a biologically plausible path to explore with your care team.

If you’ve heard that “CBD is the medicinal part” and “THC just gets you high,” Karohs wants to recalibrate your mental model. He views THC and CBD as complementary tools that work better together than alone, interacting with minor cannabinoids, terpenes, and flavonoids to amplify benefits and buffer downsides. This synergy is the famed “entourage effect,” coined by Ben-Shabat and Mechoulam, and it runs throughout the book’s science, dosing, and strain selection.

THC: more than mood

THC, first isolated by Raphael Mechoulam in 1964, binds CB1 (and CB2) receptors. Beyond euphoria and appetite stimulation, Karohs highlights research where THC induced apoptosis in leukemia cells, slowed glioblastoma growth, reduced inflammation, and aided sleep. He notes emerging use cases from PTSD processing (by modulating adverse memory) to multiple sclerosis spasticity. For cancer specifically, he cites Cristina Sánchez’s lab observations that THC exposure prompted brain cancer cells to die—a clue to its direct antitumor potential.

CBD: a non-intoxicant multitasker

CBD doesn’t intoxicate, which lowers barriers for children, elders, and THC-sensitive patients. Karohs compiles studies suggesting CBD’s role in seizure control, pain relief, anxiety reduction, anti-inflammatory action, chemo-induced neuropathy delay, and even gene expression modulation in aggressive cancers (Id-1 downregulation in breast cancer; work by California Pacific Medical Center). He underscores a safety note: CBD has “no signs of toxicity” at high doses in early studies (US patent language he cites) and can temper THC’s side effects—calming anxiety, reducing memory impairment, and lengthening therapeutic windows by slowing THC breakdown in the liver.

Why the combo matters

In Karohs’ practice, mixed THC/CBD oils outperform isolates for cancer. He references California Pacific Medical Center work where precise THC+CBD combinations injected into breast and brain tumors showed striking responses in animal models. Practically, CBD allows you to tolerate higher THC doses by blunting dysphoria, while THC brings anticancer punch CBD alone may not deliver. He cautions that “CBD-only” industrial hemp products often lack the entourage effect and may be contaminated, urging you to verify source, spectrum, and lab results (he distinguishes hempseed oil, industrial hemp extracts, and genuine cannabis oil).

The biphasic wrinkle

Dose matters. CBD can be biphasic: low and high doses can produce opposite effects. That’s why “flooding the body” can stall progress. Karohs’ rule of thumb is to use the smallest dose that achieves the medical goal, divided into multiple daily administrations to maintain steady anticancer pressure without desensitizing receptors. He warns that chronically high doses may reduce cannabinoid receptor density—a homeostatic downshift—which is counterproductive in a long fight.

(Context: Ethan Russo, M.D., whose work Karohs quotes, has argued extensively for whole-plant synergy. Mainstream medical cannabis guides like Project CBD and Integrative Oncology echo this framing, while emphasizing individualized titration and medical oversight.)

Delivery method isn’t a lifestyle choice in this book—it’s strategy. Karohs compares smoking, vaporizing, edibles, and suppositories, then explains why he migrated to oil. Your choice changes onset, duration, side-effect profile, and how precisely you can titrate dose—crucial for cancer where consistent “pressure” may matter more than peaks and valleys.

Smoking: fast but wasteful

Pros: immediate onset, easy self-titration, 2–3 hours of relief for pain. Cons: combustion creates irritants; much of the plant’s medicinal content burns away; persistent coughing and throat irritation can be issues. Karohs cites Dr. Donald Tashkin’s large study finding no link between heavy marijuana smoking and lung cancer risk—surprising even to Tashkin—but still moves away from smoke for efficiency and airway comfort.

Vaporizing: precision without combustion

Vaporizing heats flower to release cannabinoids as vapor, avoiding combustion byproducts. Karohs underscores temperature targets: roughly 284–320°F for THC, 320–356°F for CBD, ~365°F for CBN, and ~428°F for CBC—stay below 446°F to avoid benzene release. Because cannabinoids vaporize at different temps, you can re-heat the same load at staged temps to extract the full spectrum, stretching your medicine and focusing effects. He favors the Volcano Digit (Storz & Bickel) for tabletop use and the PLENTY for portable sessions, praising their consistent temperatures and clean vapor paths.

Edibles: long-lasting, hard to dose

Edibles are stealthy and prolonged (4–8 hours), but tricky. They must pass through digestion and first-pass liver metabolism—often converting THC to a more potent 11-hydroxy-THC—making onset slow (30–120 minutes) and potency variable. Karohs quotes Dr. Donald Abrams warning that many patients overshoot because they redose before the first dose peaks. He also flags sugar: refined carbs can fuel insulin and IGF pathways linked with cancer progression (he aligns here with integrative voices like Dr. Weil). If you choose edibles, watch sugars and dose low/slow.

Suppositories: niche but useful

Rectal administration can help when nausea, GI issues, or local rectal tumors limit oral use. Uptake can be steadier and bypass some GI breakdown, and you may reach higher blood levels of active compounds with fewer gut side effects. Patients still can feel THC psychoactivity at sufficient doses. Capsules (gel caps) filled with oil can double as oral doses or suppositories—handy when swallowing is difficult.

(Comparison: Many clinical programs also prefer vaporization for rapid symptom relief and tinctures/oils for sustained control. The author’s shift to oil mirrors that pattern, but he adds rigorous timing—dividing daily dose into four or five windows—to keep therapeutic concentrations steadier.)

Karohs calls cannabis oil the most potent form of medical cannabis because it concentrates the plant’s full chemical orchestra—cannabinoids, terpenes, flavonoids—into a dense, easily dosed extract. But “oil” isn’t a single thing; quality depends on plant inputs, solvents, decarboxylation, evaporation, and storage. If you’re going to use oil, he wants you to either make it safely yourself or source it from someone transparent and competent.

Solvent choice: people over petroleum

He warns against petroleum solvents like naptha or ether (historically associated with simple “RSO” methods) and favors food-grade ethanol or high-purity isopropyl alcohol for extraction, citing University of Siena findings that ethanol and olive oil preserve terpenes better. Safety first: evaporate solvents outdoors or in excellent ventilation, keep ignition sources far away, wear a respirator, and keep a proper fire extinguisher at hand. Add a few drops of water if using near-absolute alcohol to ensure alcohol fully boils off before the residual water.

Two methods, step by step

Method One: Cold (freezer) extraction. Freeze plant and alcohol overnight, combine and agitate cold, refrigerate and stir for hours, then filter through coffee filters or cloth. Evaporate gently on an induction cooktop at ~175–180°F until bubbling stops—a sign solvents have cleared. Expect slightly lower yield but higher THC preservation.

Method Two: Warm extraction. Combine plant and alcohol and simmer carefully for about two hours (on a rice cooker with thermostat or induction cooktop), then filter and evaporate as above. This “old school” approach may yield more total oil, though heat management matters.

Storage and form factors

Oil is sensitive to light and heat. Store in amber syringes or bottles, cool and dark. You can take it straight (he jokes it should taste like “a dead skunk soaked in diesel”), put it into gel capsules, or blend into topical balms (he often infuses with coconut oil for skin and joint use). For oral/suppository use, 10 mL oral syringes make dosing precise.

Buyer beware: the “CBD-only” trap

A major warning: many “CBD hemp oils” marketed online are industrial hemp byproducts—sometimes imported “sludge” from phytoremediation fields that concentrate heavy metals—sold at steep prices. They may be legal because they’re low in THC, but they often lack the entourage profile, potency, or cleanliness of genuine whole-plant cannabis extracts. His rule: if it’s freely shipped without a medical recommendation, scrutinize it. Know the difference between hempseed oil (a nutritious food oil from seeds), industrial hemp extracts (variable CBD, often poor quality), and cannabis oil (from resinous flower, with THC and CBD).

(Note: Many clinicians now insist on third-party lab tests showing cannabinoid profile, terpene content, and contaminant screening—pesticides, heavy metals, solvents, microbes. Karohs’ DIY emphasis anticipates this quality movement by urging you to own the process.)

Think of SHORAK as a training plan for your ECS and a campaign plan against cancer. It’s not “take oil when you remember.” It’s a multi-phase schedule that starts gently, builds to sustained intensity, and tapers to maintenance—while weaving in nutrition (omega-3s), timing (multiple doses per day), and discipline (no skipped days, no impulsive megadoses). Here’s how you’d follow it.

Phase 1: Starter (prime the receptors)

Before any “full strength,” you take a 7-gram blend of cannabis oil plus hempseed oil over seven days—about 25 drops per day split into five micro-doses. If you’re new to cannabis or haven’t felt effects before, this is where you “wake up” your CB receptors and let your body acclimate. Hempseed oil is not psychoactive; it supplies essential fatty acids to help you rebuild CB1 integrity.

Phase 2: Pre-treatment (ease into cannabinoids)

Two “mild” syringes (labeled M) combine cannabis and hempseed oil. You take ~0.66 grams per day (four doses of four drops) until both syringes are finished. The goal is still gentle onboarding, minimizing THC side effects while your ECS learns the rhythm of divided dosing.

Phase 3: Full treatment (constant pressure)

Eight syringes of full-strength oil—this is the anticancer engine. You take five drops, five times every 24 hours—roughly every 4.8 hours—so the cancer never enjoys an 18-hour drug holiday. Karohs estimates a traditional 60 grams over 90 days is a minimum; his extended plan totals 120 grams when you include pre- and post-phases, to smooth tolerance and recovery. If nausea makes taste intolerable, place oil in gel caps or use as suppositories. Don’t start here early. Don’t up-dose on your own. Don’t collapse five mini-doses into one big nightly hit.

Phase 4: Post-treatment (rebuild and defend)

Four syringes blend cannabis oil with hempseed oil again, at about half your full-treatment daily dose. This “cool-down” helps your immune system recover from prior conventional therapies (chemo/radiation) and may reduce relapse risk. Some patients, especially after multiple cancers, choose to remain on a maintenance dose longer-term.

Dosing rules that save you

• Smallest effective dose: Don’t flood your body; chronic high doses can down-regulate receptors.
• Divide the day: Four to five evenly spaced doses maintain steady-state levels; once-daily dosing leaves long gaps where tumors regroup.
• Never skip: If the schedule says four doses, you take four. Missing breaks the pressure pattern.

Karohs also spells out quantities for making enough oil: about 448 grams of plant material can yield the ~86 grams he uses across phases (the book uses cannabis-industry “ounces” at 28 g for calculation). If one cycle isn’t enough—especially after extensive conventional treatment—he urges continuing (some patients used up to 180 grams over six months) while staying monitored by physicians. The ethos: persistence, data, and partnership with your medical team.

Data persuades, but stories move you to act. Karohs includes dozens of letters and updates from patients and spouses—some near hospice, many told to “get affairs in order”—who report stabilization, remission, or dramatic quality-of-life improvements on SHORAK oil. He also shares hard lessons about human behavior that can make or break outcomes.

Stan: from stage 4 to remission

At 73, Stan faced leukemia, lymphoma, colon cancer, COPD, emphysema, pneumonia, and A-fib. Daily chemo pills ran $8,000 per month. Stan’s wife initially sought oil simply to soothe his last days. Instead, emails trace a turnaround: better mood and sleep within weeks, normalized lymph nodes, oncologist approvals to “keep doing whatever you’re doing,” and finally “remission” on labs. He stopped chemo pills implicated in A-fib and returned to golf.

Andrea and Viola: markers and scans shift

Andrea, with metastatic pancreatic cancer, reported blood markers back in range and shrinking liver lumps after combining internal oil with topical balms on lymph nodes. Viola, once so weak her son had to carry her, told Karohs: “Since I started taking SHORAK oil… they can no longer find the cancer,” and her oncologist paused chemo.

Bill and Dave: pain, neuropathy, relapse fears

Bill, living with chronic inflammatory demyelinating polyneuropathy and a past colon cancer, used oil and topical balms for joint pain and sleep. Subsequent scans for suspected recurrence were clear, and his labs (glucose, HDL/LDL) improved. Dave, stage 4 colon cancer, rebounded on a custom high-THC/CBD “Elephant oil” after metastases surged during an oil interruption and more chemo. He later returned to beach walks and planned a motorhome trip.

Pitfalls that sink progress

• Psychological reversal: Some say they want healing but unconsciously resist—clinging to beliefs like “I don’t deserve to be well” or “doctors would use it if it worked.” He urges frank self-inquiry and support.
• Nonadherence: Skipping doses, changing schedules, “flooding” doses, or stopping mid-course (one patient quit for a chemo trial and rapidly declined). Consistency is nonnegotiable.
• Exploitation and shortcuts: Caregivers who ignore legalities, siphon other patients’ doses, or refuse medical cards put everyone at risk. Vet helpers; stay inside the law.

(Perspective: Case reports aren’t randomized trials, and Karohs is clear that monitoring with oncologists continues throughout. Read these accounts as signals—reasons to explore—rather than definitive proof for every cancer, and always coordinate with your medical team.)

Not all cannabis is created equal. Karohs argues that modern dispensary shelves often carry heavily hybridized, immature plants bred for recreation, not medicine. His response was to breed his own medical cultivars—stabilized, aged, and selected for cannabinoid and terpene profiles tied to specific therapeutic goals. If you’re choosing strains, his framework helps you think beyond catchy names.

Start with the family tree

He distinguishes sativa, indica, and ruderalis lineages: sativas taller with longer flowering and often higher THC; indicas shorter, bushier, generally higher in CBD; ruderalis small, hardy, auto-flowering, and CBD-rich but low in THC. Modern medicine rarely uses pure lines; instead, you’ll find hybrids crafted to balance height, yield, and chemistry.

Terpenes and flavonoids: the hidden co-therapies

Terpenes like limonene (citrus-scented, antifungal, mood-lifting, anticancer in rodent studies) and others can modulate how much THC reaches your brain and your dopamine/serotonin tone. Flavonoids, including cannaflavins, can strongly inhibit inflammatory molecules like PGE-2, sometimes “30 times more effectively than aspirin,” Karohs notes. If you switch strains and feel different, it may be the terpene/flavonoid shift, not just THC/CBD.

SHORAK’s medical genetics

Karohs’ breeding playbook: start from elite landraces (e.g., Koh-Chang Thai, Black Durban, Afghan/Mazar, African Swazi), cross selectively, then backcross and clone-age plants to 7–8+ months—mimicking tropical long seasons—to deepen resin and terpene maturity. He flushes nutrients for weeks and grows organically with reverse-osmosis water. The result: targeted chemovars for oil production and symptom control.

Examples include the Senior (low THC, higher CBD) for elders and first-timers; RS-2017 (high-quality sativa influence) that coincided with a breast cancer patient’s 5-month turnaround; RS-31 and RS-37 (tilted for oil production and THC/CBD balance); CBD-OD (high CBD with 10–20% THC) as a “devastating” combo against cancer under supervision; and Elephant oil, a potent indica-forward blend that one stage 4 patient credited with renewed remission (and a fair warning about couch-lock).

Practical strain advice for you

• For cancer, look for balanced THC:CBD hybrids (e.g., Bubba Kush, Blue Dream, White Widow) and CBD-forward strains like Harlequin when new to THC.
• Ask for auto-flowering genetics (ruderalis influence) if you need higher baseline CBD.
• If a strain change derails symptom control, consider terpene profile differences and adjust.

(Context: This chemovar-first approach mirrors emerging oncology-integrative clinics that match cannabinoid ratios and terpene profiles to symptom clusters—pain, anxiety, appetite, sleep—while reserving higher THC:CBD blends for anticancer goals.)

Karohs is emphatic: do not do anything illegal. The book focuses on California law (Prop 215 and SB420; now evolved further), but the principles travel: get a legitimate physician’s medical cannabis recommendation, consider an ID card for law enforcement clarity, and source from reputable dispensaries or collectives. If you’re a caregiver, know your eligibility and responsibilities.

Your legal paper trail

In California at the time of writing, a doctor’s recommendation (not a “prescription”) is the core document. It allows possession and limited cultivation; collectives/co-ops can expand options. A state-issued Medical Marijuana Identification Card (MMIC) is optional but can smooth interactions with police and dispensaries. Beware clinics selling bogus “cultivation licenses” or operating with suspended physicians.

Choosing dispensaries and navigating products

Products often bear whimsical names and variable potencies. For cancer, Karohs suggests hybrids with meaningful CBD (Harlequin, auto-flowering genetics) and balanced THC cultivars (Chem D, Sour Diesel, Bubba Kush, Blue Dream, White Widow) when beginning—ideally verified by lab results. If you plan to make oil, ensure flower quality (organically grown, mature plants, clean of pesticides/mold) and obtain enough material for a full protocol to avoid mid-course changes.

Document, test, partner

Track doses and timing; keep copies of lab reports and recommendations; share everything with your oncologist. The theme is not anti-doctor—it’s pro-team. Karohs repeatedly urges supervision by medical professionals, routine imaging/labs to verify progress, and humility about setbacks (e.g., when one cycle is not enough, continue while monitored).

(Note: Laws have evolved since the book’s publication; always check current state and local regulations. Many jurisdictions now mandate lab testing and track-and-trace, which can make sourcing safer if you use licensed channels.)